9939 Stock Overview
A clinical-stage biotechnology company, engages in researching, developing, and commercializing therapeutic drugs for dermatology and tumors indications with the unmet medical needs in the People’s Republic of China.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Kintor Pharmaceutical Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$1.15 |
| 52 Week High | HK$3.60 |
| 52 Week Low | HK$0.79 |
| Beta | -0.14 |
| 11 Month Change | 25.00% |
| 3 Month Change | 11.65% |
| 1 Year Change | -54.18% |
| 33 Year Change | -97.35% |
| 5 Year Change | n/a |
| Change since IPO | -94.65% |
Recent News & Updates
Recent updates
Is Kintor Pharmaceutical (HKG:9939) Using Debt In A Risky Way?
Oct 07
Does Kintor Pharmaceutical (HKG:9939) Have A Healthy Balance Sheet?
Nov 16Does Kintor Pharmaceutical (HKG:9939) Have A Healthy Balance Sheet?
Apr 28Does Kintor Pharmaceutical (HKG:9939) Have A Healthy Balance Sheet?
Dec 06Is Kintor Pharmaceutical (HKG:9939) Using Debt Sensibly?
Sep 01Kintor Pharmaceutical Limited (HKG:9939) Insiders Increased Their Holdings
Feb 17What Kind Of Investors Own Most Of Kintor Pharmaceutical Limited (HKG:9939)?
Dec 23
Shareholder Returns
| 9939 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | -9.4% | -0.4% | -1.0% |
| 1Y | -54.2% | 2.7% | 20.3% |
Return vs Industry: 9939 underperformed the Hong Kong Biotechs industry which returned 2.7% over the past year.
Return vs Market: 9939 underperformed the Hong Kong Market which returned 20.3% over the past year.
Price Volatility
| 9939 volatility | |
|---|---|
| 9939 Average Weekly Movement | 11.4% |
| Biotechs Industry Average Movement | 10.5% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in HK Market | 18.9% |
| 10% least volatile stocks in HK Market | 4.3% |
Stable Share Price: 9939 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 9939's weekly volatility (11%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 175 | Youzhi Tong | www.kintor.com.cn |
Kintor Pharmaceutical Limited, a clinical-stage biotechnology company, engages in researching, developing, and commercializing therapeutic drugs for dermatology and tumors indications with the unmet medical needs in the People’s Republic of China. Its product candidates include KX-826, a potential topical drug for the treatment of androgenic alopecia and acne vulgaris; and Pruxelutamide (GT0918), a second-generation androgen receptor (AR) for the treatment of metastatic castration-resistant prostate cancer, COVID-19, and AR+ metastatic breast cancer, as well as AR-PROTAC Compound (GT20029). The company is developing Pruxelutamide (GT0918), a second generation androgen receptor (AR) for the metastatic castration-resistant prostate cancer, COVID-19, and AR+ metastatic breast cancer; GT1708F (Hedgehog/SMO Inhibitor), an inhibitor of the hedgehog signal transduction pathway to treat idiopathic pulmonary fibrosis, and blood cancer; GT0486, an inhibitor of the PI3K/mTOR signalling pathway and a second generation mTOR inhibitor for the treatment of metastatic solid tumours, such as breast cancer, prostate cancer, and hepatocellular carcinoma (HCC); and ALK-1 Antibody (GT90001), an anti-angiogenesis inhibitor and targets a new biological target activin receptor-like kinase-1 globally to treat metastatic hepatocellular carcinoma, a common type of liver cancer, and a variety of solid tumours.
Kintor Pharmaceutical Limited Fundamentals Summary
| 9939 fundamental statistics | |
|---|---|
| Market cap | HK$497.91m |
| Earnings (TTM) | -HK$1.01b |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.5x
P/E RatioIs 9939 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 9939 income statement (TTM) | |
|---|---|
| Revenue | CN¥0 |
| Cost of Revenue | CN¥41.10m |
| Gross Profit | -CN¥41.10m |
| Other Expenses | CN¥879.10m |
| Earnings | -CN¥920.20m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.13 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 59.8% |
How did 9939 perform over the long term?
See historical performance and comparison